ImmunityBio Inc. IBRX shares are down during Friday’s premarket session. However, there is no news to justify the move. The ...

Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive ...

John Zisa and Cynthia DePalma have done everything together for the past 25 years. The Bergenfeld, N.J., couple love to go ...

ImmunityBio, Inc. IBRX shares are higher on Wednesday following news that the European Commission has authorized one of the ...

Kamat has received research funding from Arquer Diagnostics, EnGene, FKD Therapies (now Ferring), the Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen, and SWOG; and ...

De Santis has declared receipt of honoraria, consultation fees, or other support from AAA, AbbVie, Amgen, Astellas, AstraZeneca, Basilea, Bayer, BMS, Eisai, Ferring ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis. Survival is comparably poor for patients who develop metastases directly after non-muscle invasive ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted ...

Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary disease, based on review of data from QUILT-3.032 ...

To reduce recurrence, immediate postoperative intravesical chemotherapy (IVC) is recommended for patients with low-risk non-muscle-invasive bladder cancer (NMIBC). This study evaluated recurrence ...